Literature DB >> 27085447

Clinical Use of Coronary CTA-Derived FFR for Decision-Making in Stable CAD.

Bjarne L Nørgaard1, Jakob Hjort2, Sara Gaur2, Nicolaj Hansson2, Hans Erik Bøtker2, Jonathon Leipsic3, Ole N Mathiassen2, Erik L Grove4, Kamilla Pedersen2, Evald H Christiansen2, Anne Kaltoft2, Lars C Gormsen5, Michael Mæng2, Christian J Terkelsen2, Steen D Kristensen2, Lars R Krusell2, Jesper M Jensen2.   

Abstract

OBJECTIVES: The goal of this study was to assess the real-world clinical utility of fractional flow reserve (FFR) derived from coronary computed tomography angiography (FFRCT) for decision-making in patients with stable coronary artery disease (CAD).
BACKGROUND: FFRCT has shown promising results in identifying lesion-specific ischemia. The real-world feasibility and influence on the diagnostic work-up of FFRCT testing in patients suspected of having CAD are unknown.
METHODS: We reviewed the complete diagnostic work-up of nonemergent patients referred for coronary computed tomography angiography over a 12-month period at Aarhus University Hospital, Denmark, including all patients with new-onset chest pain with no known CAD and with intermediate-range coronary lesions (lumen reduction, 30% to 70%) referred for FFRCT. The study evaluated the consequences on downstream diagnostic testing, the agreement between FFRCT and invasively measured FFR or instantaneous wave-free ratio (iFR), and the short-term clinical outcome after FFRCT testing.
RESULTS: Among 1,248 patients referred for computed tomography angiography, 189 patients (mean age 59 years; 59% male) were referred for FFRCT, with a conclusive FFRCT result obtained in 185 (98%). FFRCT was ≤0.80 in 31% of patients and 10% of vessels. After FFRCT testing, invasive angiography was performed in 29%, with FFR measured in 19% and iFR in 1% of patients (with a tendency toward declining FFR-iFR guidance during the study period). FFRCT ≤0.80 correctly classified 73% (27 of 37) of patients and 70% (37 of 53) of vessels using FFR ≤0.80 or iFR ≤0.90 as the reference standard. In patients with FFRCT >0.80 being deferred from invasive coronary angiography, no adverse cardiac events occurred during a median follow-up period of 12 (range 6 to 18 months) months.
CONCLUSIONS: FFRCT testing is feasible in real-world symptomatic patients with intermediate-range stenosis determined by coronary computed tomography angiography. Implementation of FFRCT for clinical decision-making may influence the downstream diagnostic workflow of patients. Patients with an FFRCT value >0.80 being deferred from invasive coronary angiography have a favorable short-term prognosis.
Copyright © 2017 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  computed tomography angiography; coronary angiography; coronary artery disease; fractional flow reserve

Mesh:

Year:  2016        PMID: 27085447     DOI: 10.1016/j.jcmg.2015.11.025

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  30 in total

1.  The diagnostic performance of SPECT-MPI to predict functional significant coronary artery disease by fractional flow reserve derived from CCTA (FFRCT): sub-analysis from ACCURACY and VCT001 studies.

Authors:  Rine Nakanishi; Kazuhiro Osawa; Indre Ceponiene; Glenn Huth; Jason Cole; Michael Kim; Negin Nezarat; Sina Rahmani; Dong Li; Souma Gupta; Campbell Rogers; Christopher Dailing; Matthew J Budoff
Journal:  Int J Cardiovasc Imaging       Date:  2017-07-11       Impact factor: 2.357

Review 2.  FFRCT for Complex Coronary Artery Disease Treatment Planning: New Opportunities.

Authors:  Jonathon Leipsic; Jonathan Weir-McCall; Philipp Blanke
Journal:  Interv Cardiol       Date:  2018-09

3.  Is there a role for fractional flow reserve in coronary artery bypass graft (CABG) planning?

Authors:  Amir Ahmadi; Dylan Stanger; John Puskas; David Taggart; Y Chandrashekhar; Jagat Narula
Journal:  Ann Cardiothorac Surg       Date:  2018-07

Review 4.  Coronary CT Angiography Derived Fractional Flow Reserve: The Game Changer in Noninvasive Testing.

Authors:  Bjarne Linde Nørgaard; Jesper Møller Jensen; Philipp Blanke; Niels Peter Sand; Mark Rabbat; Jonathon Leipsic
Journal:  Curr Cardiol Rep       Date:  2017-09-22       Impact factor: 2.931

Review 5.  Myocardial ischemia testing with computed tomography: emerging strategies.

Authors:  Prabhakar Rajiah; Christopher D Maroules
Journal:  Cardiovasc Diagn Ther       Date:  2017-10

Review 6.  Fractional flow reserve computed tomography in the evaluation of coronary artery disease.

Authors:  Shaw Hua Kueh; Matthew Boroditsky; Jonathon Leipsic
Journal:  Cardiovasc Diagn Ther       Date:  2017-10

Review 7.  Debates over NICE Guideline Update: What Are the Roles of Nuclear Cardiology in the Initial Evaluation of Stable Chest Pain?

Authors:  Sang-Geon Cho; Jahae Kim; Ho-Chun Song
Journal:  Nucl Med Mol Imaging       Date:  2019-08-28

8.  Machine learning-based CT fractional flow reserve assessment in acute chest pain: first experience.

Authors:  Matthias Eberhard; Tin Nadarevic; Andrej Cousin; Jochen von Spiczak; Ricarda Hinzpeter; Andre Euler; Fabian Morsbach; Robert Manka; Dagmar I Keller; Hatem Alkadhi
Journal:  Cardiovasc Diagn Ther       Date:  2020-08

Review 9.  Coronary Computed Tomography Angiography: Enhancing Risk Stratification and Diagnosis of Cardiovascular Disease in Women.

Authors:  Sara Karnib; Kavitha M Chinnaiyan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-10-04

10.  Impact of machine-learning CT-derived fractional flow reserve for the diagnosis and management of coronary artery disease in the randomized CRESCENT trials.

Authors:  Fay M A Nous; Ricardo P J Budde; Marisa M Lubbers; Yuzo Yamasaki; Isabella Kardys; Tobias A Bruning; Jurgen M Akkerhuis; Marcel J M Kofflard; Bas Kietselaer; Tjebbe W Galema; Koen Nieman
Journal:  Eur Radiol       Date:  2020-03-12       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.